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Introduction
Given the current SARS-CoV-2 pandemic, there has been a
signiﬁcant growth of telemedicine programs across all
specialties.1,2 Pediatric cardiology, speciﬁcally electrophysiology, where the patient population includes pediatric
patients with heart rhythm abnormalities, seems uniquely
suited to this opportunity. With the increase of commercially
available cardiac wearable devices accessible to consumers
without medical prescription, the “direct-to-consumer”
(D2C) devices, telemedicine visits can be enhanced using
real-time cardiac data/diagnostics to supplement diagnosis
and management of cardiac arrhythmias. Two prominent
D2C devices that provide real-time electrocardiogram
(ECG) data include the KardiaMobile (AliveCor, Mountain
View, CA) and the Apple Watch Series 5 (Apple, Cupertino,
CA). In this report, we present 2 pediatric cases using these
D2C cardiac devices and discuss how they have positively
impacted the telemedicine and patient experience. The
research reported in this paper adheres to the CARE case
report guidelines.

Case report
Case #1
P.P. is a 20-year-old African-American man who was
diagnosed at age 15 with paroxysmal atrial ﬁbrillation (AF)
after presenting to the emergency department with chest
pain during exertion. He had an extensive workup including
a normal echocardiogram and a diagnostic electrophysiology
study (EPS), which demonstrated no inducible arrhythmias.
Over the next several yearly ofﬁce visits, he reported having
clinical episodes of AF approximately once a year, lasting
seconds to minutes, that always spontaneously converted
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back to normal sinus rhythm. There had been no documentation of these episodes.
This year, P.P. had a telehealth visit with his pediatric
cardiac electrophysiology team. During that visit, he reported having episodes of “skipped beats” that lasted for
only a few seconds, but no concerns for AF. He did report
that he recently had purchased a new Apple Watch Series
5 but had not set up the ECG application in the Health
App. During his visit, the team assisted the patient in setting
up the application and encouraged him to obtain a real-time,
“on-demand” ECG tracing using his Apple Watch
(Figure 1). The Apple Watch Series 5 has the ability to provide continuous heart rate trends in addition to obtaining a
single-lead ECG, or “on-demand” recording. This tracing
was then e-mailed to the team, by whom a real-time assessment of his heart rate and rhythm could be performed, conﬁrming that he was in normal sinus rhythm with a rate of 89
beats per minute (bpm). In addition, the team worked with
the patient to establish a workﬂow for submission and evaluation of future tracings using the electronic medical record,
in this case using the EPIC MyChart functionality, whereby
he could securely send tracings and questions to his health
care team and the team could reply using a HIPAAcompliant mode of communication when the patient had
symptoms concerning for AF.

Case #2
P.G. is a 14-year-old female patient with a past medical
history of hypothyroidism who presented to the emergency
department with an irregular heartbeat, after having tracked
her heart rate by pulse assessment and pulse oximeter,
between 80 and 140 bpm and associated intermittent chest
pain with palpitations. Initial ECG revealed wide complex
tachycardia with left bundle branch block and inferior axis,
consistent with ventricular tachycardia (VT) arising from
the right ventricular outﬂow tract (RVOT). She underwent
EPS and transcatheter ablation and had an acutely successful
radiofrequency ablation of her RVOT-VT procedure with
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KEY FINDINGS
 Direct-to-consumer wearable devices can have a positive impact in pediatric electrophysiology telehealth
clinics by providing real-time data on heart rate and
rhythm in this population. These data can be used to
guide medical decision-making on titration of drugs
or decision to proceed to ablation therapy.
 Developing simple workﬂows to securely transmit and
integrate these electrocardiographic tracings into the
electronic medical record (in these cases, use of the MyChart application and the EPIC electronic medical record) have been described.
 There are important economic, reimbursement, workﬂow, and data integrity considerations that should be
more thoroughly explored in future studies.
recurrence of her clinical VT several hours post procedure.
The patient was started on oral verapamil and titrated to a
therapeutic dose of 120 mg every 8 hours, with signiﬁcant
decreased premature ventricular contraction (PVC) burden
and VT. The family purchased an AliveCor KardiaMobile
for assessment of her heart rate and rhythm at home during
symptomatic events. Teaching was provided prior to
discharge for family to understand the differences between sinus rhythm tracings and VT on the KardiaMobile, as well as
workﬂow teaching for transmission of tracings using MyChart to allow for a secure, HIPAA-compliant transmission.

After hospital discharge, the patient/parent transmitted
multiple ECG tracings from the KardiaMobile
demonstrating normal sinus rhythm, PVCs, and
nonsustained VT (Figure 1), which has helped guide her
outpatient medical management and drug titration. After
consecutive tracings demonstrated nonsustained VT, the
decision was made to pursue repeat EPS. Following repeat
ablation of her RVOT-VT, follow-up KardiaMobile
tracings demonstrated normal sinus rhythm with sinus
arrhythmia with no PVCs at rates of 62 to 74 bpm. Symptomatic tracings recorded for concerns of chest pain or
skipped beats conﬁrmed sinus rhythm with no PVC
recurrence. The most recent transmission acquired at the
start of a telehealth visit demonstrated sinus rhythm and
guided further conversations around ongoing arrhythmia
concerns and management.

Discussion
In this report, we describe 2 cases in which D2C cardiac
wearable ECG devices, the Apple Watch Series 5 and the
KardiaMobile, were used during telehealth visits to provide
real-time assessment of the patient’s heart rate and rhythm.
These cases represent the powerful potential role these
products may have to support and improve pediatric cardiac
electrophysiology telehealth visits. Integrating new,
commercially available technologies into electrophysiology
telemedicine clinics will be an important value-add to
deriving the most beneﬁt from these types of visits by
improving physician-patient communication, diagnosis, and
treatment of cardiac arrhythmias. Pediatric patients may be

Figure 1 Patient and physician workﬂow for obtaining and transmitting electrocardiogram (ECG) tracings from direct-to-consumer (D2C) wearable devices.
The gray workﬂow, or “Patient Workﬂow,” clariﬁes the stepwise approach the patient takes to obtain the ECG tracing, review the tracing, and upload the tracing
via the EPIC MyChart application. The screen shot images associated with each step demonstrate what the patient sees at each step. The orange workﬂow, or
“Health Care Team Workﬂow,” delineates how the message appears in the EPIC inbox (Patient Advice Request..Non-Urgent Medical Question), where
the attachment hyperlink is shown, and how to reply to the patient. AF 5 atrial ﬁbrillation; VT 5 ventricular tachycardia.
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ideally suited to these visits and technologies, as they are
often technologically savvy. Additionally, pediatric patients
may have access to their parent’s D2C wearable device for
obtaining ECG tracings.
Patient access to these technologies represents a signiﬁcant barrier to adoption. As these are D2C marketed devices,
it is not necessary for the physician to prescribe the device.
Cardiologists can play a critical role in educating patients
on available technologies, advantages and disadvantages of
each, and how certain technologies may be better for speciﬁc
patients based on their individual clinical situation. For
instance, in those patients where rhythm discrimination is
paramount, ECG monitors are preferable; in those patients
where rate determination is the primary driver for clinical
decision-making, photoplethysmography devices may be
better applicable.
Economic barriers may also represent a ﬁnancial hurdle to
widespread adoption and implementation of these devices.
The Kardia single-lead ECG monitor is currently available
for $89 and is eligible for reimbursement through a ﬂexible
spending account (FSA) or health savings account (HSA).
More recently, a 6-lead Kardia ECG monitor has received
FDA approval and is available to consumers for $149, also
eligible for FSA/HSA reimbursement. In contrast, the Apple
Watch Series 5 is currently available for $399 and is not
eligible for FSA/HSA reimbursement. For patients that
depend on insurance or FSA reimbursement to cover medical
costs, the KardiaMobile may represent a more economical
option. Both systems require a paired smartphone for full
functionality, which impacts the total cost. Patients and families with more disposable income may be more likely to
invest in a product that will provide insight into their
symptoms, diagnosis, and treatment regardless of insurance
reimbursement. Additionally, for some patients, there may
be personal stylistic preferences that may drive decisionmaking about cardiac wearables.
Simple workﬂows for secure transmission of data and
tracings should be created and provided to patients. Our
proposed solution has been to encourage patients to obtain
an ECG tracing on the day of and prior to their telehealth
visit, and to utilize the MyChart application, embedded
within our electronic medical record, EPIC, to upload the
data for review prior to/during their telehealth visit. Both
the KardiaMobile and Apple Watch Series 5 allow the user
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to save an ECG strip and easily upload tracings into the MyChart application via direct messaging to the health care team
for provider review (Figure 1).
Previous research has shown that the KardiaMobile
provides reliable data to assist in the diagnosis of pediatric
cardiac arrhythmias.3,4 In contrasting, there is little data on
the reliability of ECG data from ECGs obtained from the Apple Watch Series 5. A comparative study assessing diagnostic
quality of the Apple Watch Series 5 ECG compared to
standard 12-lead ECGs would provide important data to
support its use in an electrophysiology telehealth clinic.

Conclusion
These cases demonstrate the critical adjunctive role D2C cardiac wearable devices may have in telemedicine. Although
there are economic, reimbursement, workﬂow, and data
integrity considerations that have yet to be thoroughly
explored and deﬁned, these tools will impact the implementation of telehealth, particularly in pediatric electrophysiology telehealth clinics. Long-term patient compliance with
these devices should be assessed in future studies.
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